NCT03235375View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

April 24, 2018

Study Completion Date

April 24, 2018

Conditions

Renal Insufficiency

Interventions

DRUG

MEDI0382

MEDI0382 administered subcutaneously

Trial Locations (4)

1010

Research Site, Auckland

8011

Research Site, Christchurch

24105

Research Site, Kiel

81241

Research Site, München

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MedImmune LLC

INDUSTRY